Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice

Ye Zhao, Shikara Keshiya, Farzaneh Atashrazm, Jianqun Gao, Lars M. Ittner, Dario R. Alessi, Glenda M. Halliday, Yuhong Fu, Nicolas Dzamko (Lead / Corresponding author)

Research output: Contribution to journalArticle

2 Citations (Scopus)
96 Downloads (Pure)

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is genetically implicated in both familial and sporadic Parkinson's disease (PD). Moreover, LRRK2 has emerged as a compelling therapeutic target for the treatment of PD. Consequently, there is much interest in understanding LRRK2 and its role in PD pathogenesis. LRRK2 is constitutively phosphorylated on two serines, S910 and S935, that are required for interaction of LRRK2 with members of the 14-3-3 family of scaffolding proteins. Pathogenic LRRK2 missense mutations impair the phosphorylation of LRRK2 at these sites, but whether this contributes to PD pathology is unclear. To better understand how loss of LRRK2 phosphorylation relates to PD pathology, we have studied double knockin mice in which Lrrk2's serine 910 and 935 have both been mutated to alanine and can therefore no longer be phosphorylated. Nigrostriatal PD pathology was assessed in adult mice, aged mice, and mice inoculated with α-synuclein fibrils. Under all paradigms there was evidence of early PD pathology in the striatum of the knockin mice, namely alterations in dopamine regulating proteins and accumulation of α-synuclein. Striatal pathology was accompanied by a significant decrease in the number of astrocytes in the knockin mice. Despite striatal pathology, there was no degeneration of dopamine neurons in the substantia nigra and no evidence of a PD motor phenotype in the knockin mice. Our results suggest that modulation of LRRK2 serine 910 and 935 phosphorylation sites may have implications for dopamine turnover and astrocyte function, but loss of phosphorylation at these residues is not sufficient to induce PD neurodegeneration.

Original languageEnglish
Pages (from-to)76-87
Number of pages12
JournalNeurobiology of Disease
Volume120
Early online date5 Sep 2018
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Leucine
Astrocytes
Parkinson Disease
Phosphotransferases
Phosphorylation
Pathology
Synucleins
Corpus Striatum
Serine
Dopamine
Protein-Serine-Threonine Kinases
Dopaminergic Neurons
Substantia Nigra
Missense Mutation
Alanine
Proteins
Phenotype

Keywords

  • Astrocytes
  • Dopamine
  • Knockin mouse
  • LRRK2
  • Phosphorylation
  • Striatum
  • α-Synuclein

Cite this

Zhao, Ye ; Keshiya, Shikara ; Atashrazm, Farzaneh ; Gao, Jianqun ; Ittner, Lars M. ; Alessi, Dario R. ; Halliday, Glenda M. ; Fu, Yuhong ; Dzamko, Nicolas. / Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. In: Neurobiology of Disease. 2018 ; Vol. 120. pp. 76-87.
@article{6d7af4b71eb948918dfbba60f3fa9431,
title = "Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice",
abstract = "Leucine-rich repeat kinase 2 (LRRK2) is genetically implicated in both familial and sporadic Parkinson's disease (PD). Moreover, LRRK2 has emerged as a compelling therapeutic target for the treatment of PD. Consequently, there is much interest in understanding LRRK2 and its role in PD pathogenesis. LRRK2 is constitutively phosphorylated on two serines, S910 and S935, that are required for interaction of LRRK2 with members of the 14-3-3 family of scaffolding proteins. Pathogenic LRRK2 missense mutations impair the phosphorylation of LRRK2 at these sites, but whether this contributes to PD pathology is unclear. To better understand how loss of LRRK2 phosphorylation relates to PD pathology, we have studied double knockin mice in which Lrrk2's serine 910 and 935 have both been mutated to alanine and can therefore no longer be phosphorylated. Nigrostriatal PD pathology was assessed in adult mice, aged mice, and mice inoculated with α-synuclein fibrils. Under all paradigms there was evidence of early PD pathology in the striatum of the knockin mice, namely alterations in dopamine regulating proteins and accumulation of α-synuclein. Striatal pathology was accompanied by a significant decrease in the number of astrocytes in the knockin mice. Despite striatal pathology, there was no degeneration of dopamine neurons in the substantia nigra and no evidence of a PD motor phenotype in the knockin mice. Our results suggest that modulation of LRRK2 serine 910 and 935 phosphorylation sites may have implications for dopamine turnover and astrocyte function, but loss of phosphorylation at these residues is not sufficient to induce PD neurodegeneration.",
keywords = "Astrocytes, Dopamine, Knockin mouse, LRRK2, Phosphorylation, Striatum, α-Synuclein",
author = "Ye Zhao and Shikara Keshiya and Farzaneh Atashrazm and Jianqun Gao and Ittner, {Lars M.} and Alessi, {Dario R.} and Halliday, {Glenda M.} and Yuhong Fu and Nicolas Dzamko",
note = "Funding: MRC (MC_UU_12016/2)",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.nbd.2018.09.003",
language = "English",
volume = "120",
pages = "76--87",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Elsevier",

}

Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. / Zhao, Ye; Keshiya, Shikara; Atashrazm, Farzaneh; Gao, Jianqun; Ittner, Lars M.; Alessi, Dario R.; Halliday, Glenda M.; Fu, Yuhong; Dzamko, Nicolas (Lead / Corresponding author).

In: Neurobiology of Disease, Vol. 120, 01.12.2018, p. 76-87.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice

AU - Zhao, Ye

AU - Keshiya, Shikara

AU - Atashrazm, Farzaneh

AU - Gao, Jianqun

AU - Ittner, Lars M.

AU - Alessi, Dario R.

AU - Halliday, Glenda M.

AU - Fu, Yuhong

AU - Dzamko, Nicolas

N1 - Funding: MRC (MC_UU_12016/2)

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Leucine-rich repeat kinase 2 (LRRK2) is genetically implicated in both familial and sporadic Parkinson's disease (PD). Moreover, LRRK2 has emerged as a compelling therapeutic target for the treatment of PD. Consequently, there is much interest in understanding LRRK2 and its role in PD pathogenesis. LRRK2 is constitutively phosphorylated on two serines, S910 and S935, that are required for interaction of LRRK2 with members of the 14-3-3 family of scaffolding proteins. Pathogenic LRRK2 missense mutations impair the phosphorylation of LRRK2 at these sites, but whether this contributes to PD pathology is unclear. To better understand how loss of LRRK2 phosphorylation relates to PD pathology, we have studied double knockin mice in which Lrrk2's serine 910 and 935 have both been mutated to alanine and can therefore no longer be phosphorylated. Nigrostriatal PD pathology was assessed in adult mice, aged mice, and mice inoculated with α-synuclein fibrils. Under all paradigms there was evidence of early PD pathology in the striatum of the knockin mice, namely alterations in dopamine regulating proteins and accumulation of α-synuclein. Striatal pathology was accompanied by a significant decrease in the number of astrocytes in the knockin mice. Despite striatal pathology, there was no degeneration of dopamine neurons in the substantia nigra and no evidence of a PD motor phenotype in the knockin mice. Our results suggest that modulation of LRRK2 serine 910 and 935 phosphorylation sites may have implications for dopamine turnover and astrocyte function, but loss of phosphorylation at these residues is not sufficient to induce PD neurodegeneration.

AB - Leucine-rich repeat kinase 2 (LRRK2) is genetically implicated in both familial and sporadic Parkinson's disease (PD). Moreover, LRRK2 has emerged as a compelling therapeutic target for the treatment of PD. Consequently, there is much interest in understanding LRRK2 and its role in PD pathogenesis. LRRK2 is constitutively phosphorylated on two serines, S910 and S935, that are required for interaction of LRRK2 with members of the 14-3-3 family of scaffolding proteins. Pathogenic LRRK2 missense mutations impair the phosphorylation of LRRK2 at these sites, but whether this contributes to PD pathology is unclear. To better understand how loss of LRRK2 phosphorylation relates to PD pathology, we have studied double knockin mice in which Lrrk2's serine 910 and 935 have both been mutated to alanine and can therefore no longer be phosphorylated. Nigrostriatal PD pathology was assessed in adult mice, aged mice, and mice inoculated with α-synuclein fibrils. Under all paradigms there was evidence of early PD pathology in the striatum of the knockin mice, namely alterations in dopamine regulating proteins and accumulation of α-synuclein. Striatal pathology was accompanied by a significant decrease in the number of astrocytes in the knockin mice. Despite striatal pathology, there was no degeneration of dopamine neurons in the substantia nigra and no evidence of a PD motor phenotype in the knockin mice. Our results suggest that modulation of LRRK2 serine 910 and 935 phosphorylation sites may have implications for dopamine turnover and astrocyte function, but loss of phosphorylation at these residues is not sufficient to induce PD neurodegeneration.

KW - Astrocytes

KW - Dopamine

KW - Knockin mouse

KW - LRRK2

KW - Phosphorylation

KW - Striatum

KW - α-Synuclein

U2 - 10.1016/j.nbd.2018.09.003

DO - 10.1016/j.nbd.2018.09.003

M3 - Article

C2 - 30194047

VL - 120

SP - 76

EP - 87

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -